Healthcare company Drawbridge Health reported on Thursday the receipt of US Food and Drug Administration (FDA) 510(k) clearance for its OneDraw A1C Test System for monitoring the long-term control of blood sugar (glucose) in people with diabetes.
The OneDraw A1C Test System, which is comprised of the OneDraw Blood Collection Device and the OneDraw A1C Test, is intended for the collection and stabilisation of blood and measurement of HbA1c levels. It enables blood to be drawn quickly, comfortably and conveniently by a healthcare professional.
According to the company, the OneDraw Blood Collection Device is a small, single-use device that draws, collects and stabilises a capillary blood sample from the upper arm. The device is placed on the skin and blood is gently collected using tiny lancets with a light vacuum suction. The blood sample is then stabilised and contained within a removable cartridge, designed to protect the sample during transport.
Following the use of the OneDraw Blood Collection Device, the OneDraw A1C Test is performed by a designated certified clinical laboratory.
Based on the company's positive clinical data, the results showed a strong correlation in the HbA1c measurement obtained from samples collected using the OneDraw Blood Collection Device and those using venipuncture as well as a marked patient preference for the OneDraw Blood Collection device compared to venipuncture or fingerstick.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes